Please use this identifier to cite or link to this item:
Title: Positive-charge tuned gelatin hydrogel-siSPARC injectable for siRNA anti-scarring therapy in post glaucoma filtration surgery
Authors: Chun, Yong Yao
Yap, Zhu Li
Seet, Li Fong 
Chan, Hiok Hong
Toh, Li Zhen
Chu, Stephanie W. L.
Lee, Ying Shi
Wong, Tina T. 
Tan, Timothy T. Y.
Issue Date: 14-Jan-2021
Publisher: Nature Research
Citation: Chun, Yong Yao, Yap, Zhu Li, Seet, Li Fong, Chan, Hiok Hong, Toh, Li Zhen, Chu, Stephanie W. L., Lee, Ying Shi, Wong, Tina T., Tan, Timothy T. Y. (2021-01-14). Positive-charge tuned gelatin hydrogel-siSPARC injectable for siRNA anti-scarring therapy in post glaucoma filtration surgery. Scientific Reports 11 (1) : 1470. ScholarBank@NUS Repository.
Rights: Attribution 4.0 International
Abstract: Small interfering RNA (siRNA) therapy is a promising epigenetic silencing strategy. However, its widespread adoption has been severely impeded by its ineffective delivery into the cellular environment. Here, a biocompatible injectable gelatin-based hydrogel with positive-charge tuned surface charge is presented as an effective platform for siRNA protection and delivery. We demonstrate a two-step synthesis of a gelatin-tyramine (Gtn-Tyr) hydrogel with simultaneous charge tunability and crosslinking ability. We discuss how different physiochemical properties of the hydrogel interact with siSPARC (siRNA for secreted protein, acidic and rich in cysteine), and study the positive-charge tuned gelatin hydrogel as an effective delivery platform for siSPARC in anti-fibrotic treatment. Through in vitro studies using mouse tenon fibroblasts, the positive-charge tuned Gtn-Tyr hydrogel shows sustained siSPARC cellular internalization and effective SPARC silencing with excellent biocompatibility. Similarly, the same hydrogel platform delivering siSPARC in an in vivo assessment employing a rabbit model shows an effective reduction in subconjunctival scarring in post glaucoma filtration surgery, and is non-cytotoxic compared to a commonly used anti-scarring agent, mitomycin-C. Overall, the current siRNA delivery strategy involving the positive-charge tuned gelatin hydrogel shows effective delivery of gene silencing siSPARC for anti-fibrotic treatment. The current charge tunable hydrogel delivery system is simple to fabricate and highly scalable. We believe this delivery platform has strong translational potential for effective siRNA delivery and epigenetic silencing therapy. © 2021, The Author(s).
Source Title: Scientific Reports
ISSN: 2045-2322
DOI: 10.1038/s41598-020-80542-4
Rights: Attribution 4.0 International
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1038_s41598-020-80542-4.pdf5.13 MBAdobe PDF



Google ScholarTM



This item is licensed under a Creative Commons License Creative Commons